Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

FBCG, a large-cap growth ETF, excels in bullish markets but struggles in downturns. Learn why it's rated Hold amid current ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.